Omvoh (mirikizumab-mrkz)

Manufacturer:
Lilly
Route of Administration: 
Intravenous, Subcutaneous
Site of Care:
Outpatient
Website: 
  • Manufacturer Website

Approved Indication:

  • treatment of moderately to severely active Crohn’s disease in adults
  • treatment of moderately to severely active ulcerative colitis in adults

Conditions:

  • Crohn’s Disease
  • Ulcerative Colitis

Therapeutic Area:

  • Dermatology
  • Gastroenterology
  • Rheumatology